# MajesTEC-3 (NCT05083169)

> A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05083169
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Pomalidomide; Dexamethasone; Bortezomib; Teclistamab
- Enrollment: 587
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 145
- YouTube: 137
- Podcasts: 64
- X videos: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=majestec-3-nct05083169

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05083169", "email": "<work email>"}; the inbox owner confirms by the emailed link.